MiRNA-30 family inhibition protects against cardiac ischemic injury by regulating cystathionine-γ-lyase expression

Antioxidants and Redox Signaling

Volumn 22, Issue 3, 2015, Pages 224-240

  Shen, Yaqi ^a   Shen, Zhuqing ^a   Miao, Lei ^a   Xin, Xiaoming ^a   Lin, Shizhou ^a   Zhu, Yichun ^a   Guo, Wei ^a   Zhu, Yi Zhun ^a,b  

^a FUDAN UNIVERSITY   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CATALASE; CREATINE KINASE; CYSTATHIONINE GAMMA LYASE; HYDROGEN SULFIDE; LACTATE DEHYDROGENASE; LOCKED NUCLEIC ACID; MALONALDEHYDE; MICRORNA; MICRORNA 30; MICRORNA 30B; PROPARGYLGLYCINE; PROTEIN BAX; PROTEIN BCL 2; S PROPARGYLCYSTEINE; SMALL INTERFERING RNA; SUPEROXIDE DISMUTASE; TROPONIN I; UNCLASSIFIED DRUG; MIRN30 MICRORNA, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR SYSTEM; CELL VIABILITY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOWN REGULATION; ECHOCARDIOGRAPHY; FRACTIONAL SHORTENING; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART INJURY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HYPOXIC CARDIOMYOCYTE INJURY; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIC HEART DISEASE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEFT VENTRICULAR INTERNAL DIMENSION DIASTOLE; LEFT VENTRICULAR INTERNAL DIMENSION SYSTOLE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA ANALYSIS; UPREGULATION; ANIMAL; BINDING SITE; C57BL MOUSE; CARDIAC MUSCLE CELL; ENZYME REPRESSION; ENZYMOLOGY; GENETICS; HEK293 CELL LINE; HUMAN; KNOCKOUT MOUSE; MALE; METABOLISM; NUCLEOTIDE SEQUENCE; RNA INTERFERENCE; SPRAGUE DAWLEY RAT;

MURINAE; MUS;

ANIMALS; BASE SEQUENCE; BINDING SITES; CYSTATHIONINE GAMMA-LYASE; ENZYME REPRESSION; HEK293 CELLS; HUMANS; HYDROGEN SULFIDE; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICRORNAS; MYOCARDIAL ISCHEMIA; MYOCYTES, CARDIAC; RATS, SPRAGUE-DAWLEY; RNA INTERFERENCE;

EID: 84921024502     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2014.5909     Document Type: Article

References (46)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
2. Brennecke J, Stark A, Russell RB, and Cohen SM. Principles of microRNA-target recognition. PLoS Biol 3: e85, 2005.
3. Bridge G, Monteiro R, Henderson S, Emuss V, Lagos D, Georgopoulou D, Patient R, and Boshoff C. The microRNA-30 family targets DLL4 to modulate endothelial cell behavior during angiogenesis. Blood 120: 5063-5072, 2012.
4. Calvert JW, Coetzee WA, and Lefer DJ. Novel insights into hydrogen sulfide-mediated cytoprotection. Antioxid Redox Signal 12: 1203-1217, 2010.
5. Calvert JW, Elston M, Nicholson CK, Gundewar S, Jha S, Elrod JW, Ramachandran A, and Lefer DJ. Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemiainduced heart failure in mice. Circulation 122: 11-19, 2010.
6. Cheng CW, Wang HW, Chang CW, Chu HW, Chen CY, Yu JC, Chao JI, Liu HF, Ding SL, and Shen CY. MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer. Breast Cancer Res Treat 134: 1081-1093, 2012.
7. Cindrova-Davies T, Herrera EA, Niu Y, Kingdom J, Giussani DA, and Burton GJ. Reduced cystathionine clyase and increased miR-21 expression are associated with increased vascular resistance in growth-restricted pregnancies: hydrogen sulfide as a placental vasodilator. Am J Pathol 182: 1448-1458, 2013.
8. Dalmay T. Mechanism of miRNA-mediated repression of mRNA translation. Essays Biochem 54: 29-38, 2013.
9. Doench JG and Sharp PA. Specificity of microRNA target selection in translational repression. Genes Dev 18: 504-511, 2004.
10. Dongó E, Hornyák I, Benk}o Z, and Kiss L. The cardioprotective potential of hydrogen sulfide in myocardial ischemia/reperfusion injury (Review). Acta Physiol Hung 98: 369-381, 2011.
11. Dong S, Cheng Y, Yang J, Li J, Liu X, Wang X, Wang D, Krall TJ, Delphin ES, and Zhang C. MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J Biol Chem 284: 29514-29525, 2009.
12. Downey JM and Cohen MV. Why do we still not have cardioprotective drugs Circ J 73: 1171-1177, 2009.
13. Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, van der Made I, Herias V, van Leeuwen RE, Schellings MW, Barenbrug P, Maessen JG, Heymans S, Pinto YM, and Creemers EE. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of micro-RNAs in myocardial matrix remodeling. Circ Res 104: 170-178, 6p following 178, 2009.
14. Elrod JW, Calvert JW, Morrison J, Doeller JE, Kraus DW, Tao L, Jiao X, Scalia R, Kiss L, and Szabo C. Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. Proc Natl Acad Sci USA 104: 15560-15565, 2007.
15. Fiedler J, Batkai S, and Thum T. MicroRNA-based therapy in cardiology. Herz 39: 194-200, 2014.
16. Fiedler J, Jazbutyte V, Kirchmaier BC, Gupta SK, Lorenzen J, Hartmann D, Galuppo P, Kneitz S, Pena JT, and Sohn-Lee C. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 124: 720-730, 2011.
17. Geng B, Chang L, Pan C, Qi Y, Zhao J, Pang Y, Du J, and Tang C. Endogenous hydrogen sulfide regulation of myocardial injury induced by isoproterenol. Biochem Biophys Res Commun 318: 756-763, 2004.
18. Hullinger TG, Montgomery RL, Seto AG, Dickinson BA, Semus HM, Lynch JM, Dalby CM, Robinson K, Stack C, and Latimer PA. Inhibition of miR-15 protects against cardiac ischemic injury novelty and significance. Circ Res 110: 71-81, 2012.
19. Ikeda S, Kong SW, Lu J, Bisping E, Zhang H, Allen PD, Golub TR, Pieske B, and Pu WT. Altered microRNA expression in human heart disease. Physiol Genomics 31: 367-373, 2007.
20. Jentzsch C, Leierseder S, Loyer X, Flohrschutz I, Sassi Y, Hartmann D, Thum T, Laggerbauer B, and Engelhardt S. A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes. J Mol Cell Cardiol 52: 13-20, 2012.
21. Liu J, Hao D-D, Zhang J-S, and Zhu Y-C. Hydrogen sulphide inhibits cardiomyocyte hypertrophy by up-regulating miR-133a. Biochem Biophys Res Commun 413: 342-347, 2011.
22. Liu Y-H, Lu M, Hu L-F, Wong PT-H, Webb GD, and Bian J-S. Hydrogen sulfide in the mammalian cardiovascular system. Antioxid Redox Signal 17: 141-185, 2012.
23. Long G, Wang F, Duan Q, Yang S, Chen F, Gong W, Yang X, Wang Y, Chen C, and Wang DW. Circulating miR-30a, miR-195 and let-7b associated with acute myocardial infarction. PLoS One 7: e50926, 2012.
24. Obad S, dos Santos CO, Petri A, Heidenblad M, Broom O, Ruse C, Fu C, Lindow M, Stenvang J, and Straarup EM. Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 43: 371-378, 2011.
25. Pan LL, Liu XH, Gong QH, Yang HB, and Zhu YZ. Role of cystathionine c-lyase/hydrogen sulfide pathway in cardiovascular disease: a novel therapeutic strategy Antioxid Redox Signal 17: 106-118, 2012.
26. PanW, ZhongY,ChengC,Liu B,Wang L, LiA, Xiong L, and Liu S. MiR-30-regulated autophagy mediates angiotensin IIinduced myocardial hypertrophy. PLoS One 8: e53950, 2013.
27. Pan Z, Sun X, Shan H, Wang N, Wang J, Ren J, Feng S, Xie L, Lu C, and Yuan Y. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-b1 pathway clinical perspective. Circulation 126: 840-850, 2012.
28. Qipshidze N, Metreveli N, Mishra PK, Lominadze D, and Tyagi SC. Hydrogen sulfide mitigates cardiac remodeling during myocardial infarction via improvement of angiogenesis. Int J Biol Sci 8: 430, 2012.
29. Rakhit RD, Edwards RJ, Mockridge JW, Baydoun AR, Wyatt AW, Mann GE, and Marber MS. Nitric oxide-induced cardioprotection in cultured rat ventricular myocytes. Am J Physiol Heart Circ Physiol 278: H1211-H1217, 2000.
30. Sayed D, Hong C, Chen I-Y, Lypowy J, and Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 100: 416-424, 2007.
31. Shen J, Xing T, Yuan H, Liu Z, Jin Z, Zhang L, and Pei Y. Hydrogen sulfide improves drought tolerance in Arabidopsis thaliana by MicroRNA expressions. PLoS One 8: e77047, 2013.
32. Shibuya N, Tanaka M, Yoshida M, Ogasawara Y, Togawa T, Ishii K, and Kimura H. 3-Mercaptopyruvate sulfurtransferase produces hydrogen sulfide and bound sulfane sulfur in the brain. Antioxid Redox Signal 11: 703-714, 2009.
33. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, Doevendans PA, Mummery CL, Borlak J, and Haverich A. MicroRNAs in the human heart a clue to fetal gene reprogramming in heart failure. Circulation 116: 258-267, 2007.
34. Toldo S,Das A, Mezzaroma E,Chau VQ, Marchetti C, Durrant D, Samidurai A, Van Tassell BW, Yin C, Ockaili RA, Vigneshwar N, Mukhopadhyay ND, Kukreja RC, Abbate A, and Salloum FN. Induction of MicroRNA-21 with exogenous hydrogen sulfide attenuates myocardial ischemic and inflammatory injury in mice. Circ Cardiovasc Genet 7: 311-320, 2014.
35. Toub N, Malvy C, Fattal E, and Couvreur P. Innovative nanotechnologies for the delivery of oligonucleotides and siRNA. Biomed Pharmacother 60: 607-620, 2006.
36. Van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, Hill JA, and Olson EN. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 105: 13027-13032, 2008.
37. Wang J, Guan X, Guo F, Zhou J, Chang A, Sun B, Cai Y, Ma Z, Dai C, Li X, and Wang B. miR-30e reciprocally regulates the differentiation of adipocytes and osteoblasts by directly targeting low-density lipoprotein receptorrelated protein 6. Cell Death Dis 4: e845, 2013.
38. Wang Q, Liu H-R, Mu Q, Rose P, and Zhu YZ. S-propargylcysteine protects both adult rat hearts and neonatal cardiomyocytes from ischemia/hypoxia injury: the contribution of the hydrogen sulfide-mediated pathway. J Cardiovasc Pharmacol 54: 139-146, 2009.
39. Wang Q, Wang X-L, Liu H-R, Rose P, and Zhu Y-Z. Protective effects of cysteine analogues on acute myocardial ischemia: novel modulators of endogenous H2S production. Antioxid Redox Signal 12: 1155-1165, 2010.
40. Wang R. Two's company, three's a crowd: can H2S be the third endogenous gaseous transmitter FASEB J 16: 1792-1798, 2002.
41. Wang X, Wang Q, Guo W, and Zhu Y. Hydrogen sulfide attenuates cardiac dysfunction in a rat model of heart failure: a mechanism through cardiac mitochondrial protection. Biosci Rep 31: 87-98, 2011.
42. Wei C, Li L, and Gupta S. NF-kappaB-mediated miR-30b regulation in cardiomyocytes cell death by targeting Bcl-2. Mol Cell Biochem 387: 135-141, 2014.
43. Yang B, Lin H, Xiao J, Lu Y, Luo X, Li B, Zhang Y, Xu C, Bai Y, and Wang H. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 13: 486-491, 2007.
44. Yang G, Pei Y, Cao Q, and Wang R. MicroRNA-21 represses human cystathionine gamma-lyase expression by targeting at specificity protein-1 in smooth muscle cells. J Cell Physiol 227: 3192-3200, 2012.
45. Yellon DM and Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 357: 1121-1135, 2007.
46. Zhu YZ, Wang ZJ, Ho P, Loke YY, Zhu YC, Huang SH, Tan CS, Whiteman M, Lu J, and Moore PK. Hydrogen sulfide and its possible roles in myocardial ischemia in experimental rats. J Appl Physiol 102: 261-268, 2007.